Libido & sexual wellness peptides, cross-examined.
2 libido and sexual wellness peptides tracked on Peptigrity, with independent HPLC purity data, shop coverage and mechanism research for each. The category covers two distinct mechanisms: melanocortin receptor activation (PT-141, FDA-approved for a defined indication in women) and kisspeptin-GnRH pathway stimulation (Kisspeptin, the upstream regulator of the entire reproductive endocrine axis). Both compounds operate centrally, not peripherally - they modulate brain pathways that drive sexual response rather than acting directly on genital vasculature.
Figures updated
How to choose between libido peptides
The two compounds in this category target very different parts of the sexual-response system. Choose based on the specific mechanism being researched - central melanocortin signaling for sexual desire and arousal, or upstream reproductive hormone regulation through the kisspeptin-GnRH axis.
PT-141 (Bremelanotide)
Class: Synthetic cyclic heptapeptide · Mechanism: MC4R agonism, central nervous system · Status: FDA-approved as Vyleesi
Human RCT (Phase 3)Kisspeptin
Class: Neuropeptide encoded by KISS1 · Mechanism: GPR54/KISS1R activation, upstream of GnRH · Status: Research-only
Human research (clinical investigations)The Skin, Anti-Aging & Cosmetic category contains Melanotan II, the parent melanocortin agonist from which PT-141 was derived. Melanotan II is sometimes researched in libido contexts informally - its broader melanocortin receptor activity (including MC4R) produces sexual response effects in addition to the pigmentation it's primarily known for. PT-141 is the more selective compound for sexual response specifically.
Compounds in this category
| Compound | Avg purity | Lab tests | Shops listing it |
|---|---|---|---|
Melanocortin receptor agonist (bremelanotide) FDA-approved as Vyleesi® for hypoactive sexual desire disorder in premenopausal women. | 99.7% | 274 | 426 |
Neuropeptide encoded by the KISS1 gene, researched for reproductive hormone regulation, puberty onset, and fertility treatment. | 99.4% | 172 | 360 |
Lab tests link to each compound's lab-test page. Purity dots: ≥98% green · 95–98% purple · 90–95% amber · under 90% red (the /lab-tests bands). “Shops listing it” counts shops that list the compound, tested or not.
Mechanism overview
The two compounds operate on distinct levels of the sexual-response system: PT-141 targets central melanocortin signaling that drives sexual desire and arousal, while Kisspeptin acts upstream on the reproductive endocrine axis itself.
PT-141 acts on the brain rather than on peripheral genital tissue. The melanocortin system, particularly MC4R-expressing neurons in the hypothalamus, plays a documented role in sexual desire and arousal across mammalian species. PT-141 binds MC4R in this central region, triggering downstream dopamine release in brain regions associated with sexual response. The compound's clinical effect - increased sexual desire and arousal in HSDD patients - is therefore upstream of the peripheral processes that PDE5 inhibitors (sildenafil, tadalafil) target. The two drug classes are complementary rather than competing, and address different aspects of sexual response. PT-141's mechanism also explains its observed side-effect profile: nausea, transient hyperpigmentation, and blood pressure changes are documented in clinical trials, all consistent with melanocortin pathway activation.
Kisspeptin operates further upstream still. The hypothalamic-pituitary-gonadal axis begins with hypothalamic kisspeptin neurons, which release kisspeptin onto GnRH neurons; GnRH then triggers LH and FSH release from the pituitary; LH and FSH drive testosterone production in men or estradiol production in women. Kisspeptin sits at the apex of this cascade. Loss of kisspeptin signaling causes complete failure of reproductive endocrine function (hypogonadotropic hypogonadism); restoration of signaling restores reproductive function. Clinical research has investigated kisspeptin administration in controlled ovarian stimulation protocols, hypothalamic amenorrhea, and other contexts where restoration of upstream reproductive signaling is the goal. The compound is mechanistically distinct from libido-acting drugs - it's a reproductive endocrinology research compound that happens to be tracked here because of the broader category framing.
For deeper background on peptide manufacturing and verification, see how peptides are made.
⚠ Quality verification: PT-141 and Kisspeptin have distinct verification profiles
The two compounds in this category have different verification considerations:
PT-141 - MELANOTAN II SUBSTITUTION RISK: PT-141 (bremelanotide) is a specific metabolite of melanotan II with cyclic structure. Some vendors ship melanotan II under PT-141 labeling, particularly when pricing diverges sharply from market norms. Mass spectrometry molecular weight verification distinguishes the two compounds clearly. The compounds are related but not interchangeable - MT-2 has broader receptor activity including MC1R (pigmentation) that PT-141 does not.
KISSPEPTIN FRAGMENT AMBIGUITY: "Kisspeptin" is sold as multiple fragments - Kisspeptin-10, Kisspeptin-13, Kisspeptin-54 - with different lengths and pharmacokinetic profiles. Kisspeptin-10 is the most common research form, but vendors do not always specify which fragment they ship. Mass spectrometry confirms the specific fragment.
LIMITED INDEPENDENT DATA: With only two compounds in this category and PT-141 being the higher-volume option, independent test coverage on Kisspeptin specifically is thinner. Per-compound test counts are visible on the individual cards above.
Frequently asked questions
Yes, for a specific indication. PT-141 (bremelanotide) was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Approval is restricted to that indication; off-label use in men, postmenopausal women, or for non-HSDD applications is not FDA-approved. The compound is administered by subcutaneous injection on an as-needed basis (45 minutes before anticipated sexual activity), with a maximum dose frequency to manage cardiovascular and nausea-related side effects.
Yes mechanistically; not FDA-approved for that use. The melanocortin pathway PT-141 activates exists in both male and female brains, and preclinical and small-scale clinical research has documented PT-141 effects on male sexual response - the compound was originally developed in part for male erectile dysfunction before pivoting to the female HSDD indication that ultimately gained FDA approval. Off-label research interest in male applications continues, but no Phase 3 program has been pursued for FDA male-indication approval. Buyers researching male applications should understand they're operating outside the regulatory indication.
PT-141 is a metabolite of Melanotan II with selectivity changes that make it more focused on MC4R (sexual response) and less active at MC1R (pigmentation). The two compounds share mechanism class - both are melanocortin receptor agonists - but produce different clinical effects. Melanotan II's broader receptor activity produces both sexual response effects AND pigmentation; PT-141's narrower selectivity produces predominantly sexual response effects. For pigmentation research, Melanotan II is in the Skin, Anti-Aging & Cosmetic category. For sexual response research specifically, PT-141 is the more selective compound.
Not really, by mechanism. Kisspeptin is upstream of the entire reproductive endocrine axis - it controls LH and FSH release, which control testosterone and estradiol production. It is appropriately thought of as a reproductive endocrinology research compound rather than a libido-specific compound. Kisspeptin sits in this category because of the broader framing of "sexual wellness" rather than because it acts on sexual desire or arousal pathways the way PT-141 does. Research interest is in fertility, hypothalamic amenorrhea, and reproductive hormone restoration, not in acute libido enhancement.
The FDA-approved dose for Vyleesi is 1.75 mg administered subcutaneously at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than 8 doses per month. Research peptide PT-141 protocols vary; most follow similar dosing logic with the understanding that exceeding the FDA-labeled frequency increases cardiovascular and nausea-related side effect risk. Use the general peptide calculator and BAC water calculator for reconstitution math.
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.